Han Biomedical

Han Biomedical Receivables

The Accounts Receivable of Han Biomedical (6999.TWO) as of Nov 3, 2026 is 33.60 M TWD. In the previous year, Accounts Receivable was 32.51 M TWD — a change of 3.37% (higher).

Receivables

33.60 MTWD

YoY

3.37%

Last updated:

Accounts Receivable of Han Biomedical is 2024 33.60 M TWD. Accounts Receivable of Han Biomedical was 2023 32.51 M TWD. It decreases by 3.37% higher compared to the previous year.

The Han Biomedical Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2022
29.71 M TWD
Jan 1, 2023
32.51 M TWD
Jan 1, 2024
33.60 M TWD
The Han Biomedical Receivables history
YEARReceivablesYoY
33.60 MTWD+3.37%
32.51 MTWD+9.42%
29.71 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Han Biomedical Stock analysis

What does Han Biomedical do? Han Biomedical Inc generates revenue through the design, development, and production of medical materials for tissue reconstruction and repair. Its primary products are BarriGel, a post-surgical anti-adhesion solution that prevents complications by extending degradation time, and Hancare, a collagen scaffolding material made from medical-grade collagen that adheres to wounds and absorbs exudate. The company distributes these products mainly within Taiwan's domestic market, targeting healthcare providers and medical facilities that require advanced tissue repair solutions. The firm focuses on natural biomedical materials, emphasizing product innovation for post-surgical care. BarriGel and Hancare are positioned as specialized medical solutions for wound management and adhesion prevention, catering to hospitals and clinics seeking effective tissue repair technologies. Revenue streams are derived from direct sales of these branded products to domestic healthcare institutions without external distribution channels. Han Biomedical Inc's business model centers on proprietary medical materials developed for specific clinical applications. The company's product portfolio includes BarriGel and Hancare, both designed to address post-surgical challenges with natural materials. Domestic market distribution ensures consistent revenue from local healthcare providers who prioritize advanced tissue repair solutions. Han Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Han Biomedical stock

Accounts Receivable of Han Biomedical is 33.60 M TWD in 2024.

Accounts Receivable of Han Biomedical changed from 32.51 M TWD to 33.60 M TWD, representing a 3.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Han Biomedical since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Han Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Han Biomedical

All Key Metrics — Han Biomedical